Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Abstract: The promise of model-predictive control (MPC) in robotics has led to extensive development of efficient numerical optimal control solvers in line with differential dynamic programming ...
VALDOSTA — With a focus on developing forward-thinking, future-ready graduates with the skills, knowledge, and agility needed to succeed in a rapidly evolving global landscape, Valdosta State ...
Chip programming solutions provider Data I/O was recently targeted in a ransomware attack that has caused significant disruption to the company’s operations. Data I/O offers electronic device ...
The Defense Advanced Research Projects Agency (DARPA) is taking a significant step toward overcoming the challenges of assembling large-scale structures in orbit by testing new in-space manufacturing ...
Most people are familiar with data in the form of a spreadsheet, with labeled columns of different data types such as name, address, age, and so on. Databases work the same way, with each table laid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback